Agios Pharmaceuticals, Inc. AGIO

Updated: 17 Jun 2026

NASDAQ | Biotech | Biotech, rare diseases

No signal published yet

We already track Agios Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Agios Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotech, rare diseases
We're already tracking Agios Pharmaceuticals, Inc. — here are the latest events we've registered

Recent News

  • On June 13, 2026, Agios presented Phase 3 RISE UP results for mitapivat in sickle cell disease at the EHA Congress. The company also recently entered an exclusive global license agreement with Oscotec to develop a SYK inhibitor.

What Firelda Watch includes for Agios Pharmaceuticals, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Agios Pharmaceuticals, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Black Mammoth Metals Corp
BMM
NEUTRAL
Hansa Biopharma AB (publ)
HNSA
HOLD
Crustal Resources B
HOLD
Crustal Minerals
CRUST B
NEUTRAL
Bioarctic
BIOA B
BUY

Biotech

More companies in this sector

Want to follow Agios Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Agios Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Agios Pharmaceuticals, Inc. AGIO
Agios Pharmaceuticals — follow and we'll monitor it
Follow Agios Pharmaceuticals free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.